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Does the N-terminus of BRCA1 Ubiquitinate Topoisomerase II? 
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Introduction 
 
Breast cancer is one of the diseases women fear most 
(www.mayoclinic.org) and is currently under intense 
study. Germline mutations in the BRCA1 gene account 
for about 40-50% of all hereditary cases of breast 
cancer (Fan et al, 1999). BRCA1 is a 220-kDa multi-
functional nuclear phosphoprotein that functions in 
transcription, DNA repair mechanisms, apoptosis, cell-
cycle progression, ubiquitin ligase activity and 
maintenance of genomic integrity (Starita and Parvin, 
2003; Fan et al, 2001). BRCA1 interacts with an 
astronomical number of proteins; therefore, determining 
its binding regions is important in predicting the effect of 
mutations in different parts of the BRCA1 gene. 
 A recent study by Lou et al. showed that 
knocking down either BRCA1 or topoisomerase II in 
HCC1937 cells (breast cancer cell line) and HeLa cells 
resulted in defective chromosome condensation and 
lagging chromosomes during mitosis. Thus, BRCA1 
plays a role in DNA decatenation. Previously, Baer and 
Ludwig showed that the N-terminus of BRCA1 forms a 
heterodimer with BARD1, and together this complex 
acts as an active ubiquitin polymerase. Lou et al. found 
that topoisomerase II immunoprecipitated from cells 
that produced endogenous BRCA1 was ubiquitinated, 
while topoisomerase II from cells lacking BRCA1 was 
not ubiquitinated. Furthermore, ubiquitination of 
topoisomerase II lead to an increase in its activity. 
However, no evidence was shown for a direct role of 
BRCA1 in ubiquitinating topoisomerase II. Is BRCA1 
directly interacting with topoisomerase II, 
ubiquitinating it through its N-terminus, or is it playing a 
role as an upstream regulator of topoisomerase II? 
 Determining whether the N-terminus of 
BRCA1 is ubiquitinating topoisomerase II will lead to a 
better understanding of BRCA1’s numerous functions. 
Furthermore, germline mutations in the N-terminus of 
BRCA1 can be predicted to have an adverse effect on 
topoisomerase II activity, leading to defective 
chromosome condensation, which could be targeted for 
therapy. 
 
Specific Aims 
 
The first goal is to make a HeLa cell line which has 
exons 2, 3, 4 and 5 of the BRCA1 gene floxed. Floxing 
these exons will lead to the deletion of the N-terminus 
in the BRCA1 protein when these HeLa cells will be 
transfected with the retroviral vector encoding the Cre 
recombinase protein (Loonstra et al, 2001). It is 
hypothesized that deleting the N-terminus of the 
BRCA1 protein will make BRCA1 unable to ubiquitinate 
topoisomerase II. 
The second goal of this proposal is to 
determine whether topoisomerase II is ubiquitinated in 
HeLa cells expressing the truncated BRCA1 protein. 
____________________________________________ 
 
* This author wrote the paper for Biology 352: Molecular Genetics, taught 
by Dr. Karen Kirk.  
Topoisomerase II will be immunoprecipitated and 
probed for antibodies to ubiquitin. Ubiquitination of 
topoisomerase II in cells expressing normal BRCA1 
and non-ubiquitinated topoisomerase II in cells 
expressing truncated BRCA1 will provide direct 
evidence for the role of the N-terminus of the BRCA1 
protein in ubiquitinating topoisomerase II. 
 
Experimental Procedure 
 
Previous research has shown that topoisomerase II 
ubiquitination requires BRCA1. However, it is not clear 
if BRCA1 is directly involved in the ubiquitination of 
topoisomerase II. In order to test the hypothesis that 
the N-terminus of BRCA1 is directly involved in 
topoisomerase II ubiquitination, a HeLa cell line will be 
generated which produces a version of the BRCA1 
protein lacking the N-terminus. The intron sequences 
flanking exon 2 on the 5’ end and exon 5 on the 3’ end 
will be obtained from the NCBI website. Then, loxP 
sites will be inserted into these intronic sequences in 
the genome of HeLa cells by using a modified SW137 
targeting vector (Williams et al, 1994). This vector will 
be engineered to have regions of homology flanking the 
two loxP sites. The neomycin gene will be inserted after 
the 5’ loxP site, followed by the DNA sequences of the 
exons and introns of the N-terminus of BRCA1. The 
second loxP site (3’ loxP) will flank exon 5 of BRCA1, 
followed by a large region of homology and then by the 
thymidine kinase (TK) gene. After the HeLa cells are 
infected with this linearized vector by electroporation, 
selection will be done by adding G418 (Williams et al, 
1994). Furthermore, to determine whether non-
homologous recombination occurred, ganciclovir will be 
added to the cells selected with G418 resistance. If 
non-homologous recombination has occurred, the TK 
gene will be retained and ganciclovir addition will kill 
cells.  
 Next, since the HeLa cells do not produce the 
Cre recombinase enzyme, these cells will be 
transfected with a retroviral construct containing Cre 
fused to GFP. This retroviral vector is replication-
defective (Loonstra et al, 2001). To infect the HeLa 
cells, they will be incubated with retroviral supernatant 
in the presence of polybrene. To determine whether the 
transfections have been successful, FACScalibur 
flowcytometer (Benton Dickinson) and CELL QUEST 
software analyses will be performed as transfected cells 
synthesize GFP (Loonstra et al, 2001). 
 To make sure that the loxP-Cre site-specific 
recombination system has indeed worked and the 
BRCA1 made in these cells is truncated, a western blot 
analysis will be done. The size of the truncated protein 
is expected to be about 20kDa smaller than the normal 
BRCA1 protein (220 kDa). Anti-tubulin will be used as 
the loading control. For the negative control, cells 
transfected with the modified SW137 targeting vector, 
but not transfected with the Cre recombinase enzyme 
will be probed for BRCA1. This band would show the 
size of normal BRCA1. 
 Finally, to determine whether this truncated 
BRCA1 protein is able to ubiquitinate topoisomerase 
II, immunoprecipitation will be done. Topoisomerase 
II will be immunoprecipitated from HeLa cells 
producing truncated BRCA1, as well as from HeLa cells 
producing normal BRCA1. The antibodies will be 
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obtained from NeoMarkers (Lou et al, 2005). Next, the 
protein-antibody complexes will be run on 
polyacrylamide gels and probed with antibodies to 
ubiquitin. As a positive control, the immunoprecipitate 
will be blotted with antibodies to topoisomerase II. 
This positive control will indicate any topoisomerase II 
immunoprecipitation from the cells. 
 The lane with topoisomerase II from HeLa 
cells making truncated BRCA1 would be expected not 
to show any band for ubiquitin; the lane with 
topoisomerase II from HeLa cells with normal BRCA1 
may show a band at slightly over 220 kDa, indicating 
that topoisomerase II has been ubiquitinated. 
However, if topoisomerase II immunoprecipitated from 
HeLa cells making truncated BRCA1 show 
ubiquitination, it would suggest that the N-terminus of 
BRCA1 is not involved in the ubiquitination of 
topoisomerase II. BRCA1 may be regulating 
topoisomerase II by activating other proteins capable 
of ubiquitin ligase activity (independent of its N-
terminus). 
 Since a negative result would support the 
given hypothesis, it is necessary to check that the 
negative result does not occur because of other factors 
besides the loss of the N-terminus of BRCA1. It is 
possible that the truncated BRCA1 protein is unstable 
and degrades after being expressed for only a few 
hours.  In order to test whether BRCA1 is transiently 
expressed, a time-course western blot can be done. 
However, to do this, the HCC1937 cell line (which does 
not produce functional BRCA1) must be transfected 
with a vector containing the truncated BRCA1 under an 
inducible promoter.  
 To be able to control BRCA1 expression in 
HCC1937 cells, two transfections must be performed as 
outlined in the Complete Control® Inducible 
Mammalian Expression System from the Stratagene 
Company (www.stratagene.com). First, cells are 
transfected with a pVER3 plasmid, which contains the 
gene for a synthetic ecdysone receptor under the CMV 
promoter that is constitutively expressed. This plasmid 
also has the kanamycin resistance gene, allowing for 
selection of transfected cells. The second plasmid, 
pEGSH, contains a synthetic ecdysone response 
element upstream of the promoter of the gene of 
interest;  the ecdysone receptor (transcribed from the 
pERV3 plasmid) binds to this element and constitutively 
represses the promoter. The pEGSH plasmid has the 
hygromycin resistance gene, allowing transfected cells 
to survive in the presence of hygromycin. Addition of 
ecdysone allows the basal transcription machinery to 
bind to the promoter (since the receptor can no longer 
repress the promoter) and for the gene of interest to be 
expressed. The truncated BRCA1 cDNA will be inserted 
downstream of the promoter in the pEGSH plasmid, 
and ecdysone will be added when BRCA1 expression is 
to be induced. Thus, the cells can be lysed and probed 
for BRCA1 at a number of time intervals after BRCA1 
expression.  
 A time-course western blot may show that 
HCC1937 cells expressing truncated BRCA1 have the 
same intensity of bands when probed for BRCA1 at 
different time intervals post expression. This would 
indicate that truncated BRCA1 is stable in cells. The 
immunoprecipitation experiment (of topoisomerase II) 
may then be repeated in the HCC1937 cells to check 
for topoisomerase II ubiquitination. 
 
 
 
Conclusion 
 
These experiments will determine whether the N-
terminus of BRCA1 is involved in the ubiquitination of 
the topoisomerase II enzyme. This research will add 
to the known functions of BRCA1 and increase our 
understanding of this vital protein. Furthermore, 
mutations in the N-terminus of BRCA1 can be predicted 
to cause lagging chromosomes, and therapy could be 
targeted at the ubiquitination of topoisomerase II.  
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